Cargando…

PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol

BACKGROUND: A "physiologically based pharmacokinetic" (PBPK) approach uses a realistic model of the animal to describe the pharmacokinetics. Previous PBPKs have been designed for specific solutes, required specification of a large number of parameters and have not been designed for general...

Descripción completa

Detalles Bibliográficos
Autor principal: Levitt, David G
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC126244/
https://www.ncbi.nlm.nih.gov/pubmed/12182760
http://dx.doi.org/10.1186/1472-6904-2-5
_version_ 1782120325824118784
author Levitt, David G
author_facet Levitt, David G
author_sort Levitt, David G
collection PubMed
description BACKGROUND: A "physiologically based pharmacokinetic" (PBPK) approach uses a realistic model of the animal to describe the pharmacokinetics. Previous PBPKs have been designed for specific solutes, required specification of a large number of parameters and have not been designed for general use. METHODS: This new PBPK program (PKQuest) includes a "Standardhuman" and "Standardrat" data set so that the user input is minimized. It has a simple user interface, graphical output and many new features: 1) An option that uses the measured plasma concentrations to solve for the time course of the gastrointestinal, intramuscular, intraperotineal or skin absorption and systemic availability of a drug – for a general non-linear system. 2) Capillary permeability limitation defined in terms of the permeability-surface area products. 4) Saturable plasma and tissue protein binding. 5) A lung model that includes perfusion-ventilation mismatch. 6) A general optimization routine using either a global (simulated annealing) or local (Powell) minimization applicable to all model parameters. RESULTS: PKQuest was applied to measurements of human propranolol pharmacokinetics and intestinal absorption. A meal has two effects: 1) increases portal blood flow by 50%; and 2) decreases liver metabolism by 20%. There is a significant delay in the oval propranolol absorption in fasting subjects that is absent in fed subjects. The oral absorption of the long acting form of propranolol continues for a period of more than 24 hours. CONCLUSIONS: PKQuest provides a new general purpose, easy to use, freely distributed and physiologically rigorous PBPK software routine.
format Text
id pubmed-126244
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-1262442002-09-19 PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol Levitt, David G BMC Clin Pharmacol Research Article BACKGROUND: A "physiologically based pharmacokinetic" (PBPK) approach uses a realistic model of the animal to describe the pharmacokinetics. Previous PBPKs have been designed for specific solutes, required specification of a large number of parameters and have not been designed for general use. METHODS: This new PBPK program (PKQuest) includes a "Standardhuman" and "Standardrat" data set so that the user input is minimized. It has a simple user interface, graphical output and many new features: 1) An option that uses the measured plasma concentrations to solve for the time course of the gastrointestinal, intramuscular, intraperotineal or skin absorption and systemic availability of a drug – for a general non-linear system. 2) Capillary permeability limitation defined in terms of the permeability-surface area products. 4) Saturable plasma and tissue protein binding. 5) A lung model that includes perfusion-ventilation mismatch. 6) A general optimization routine using either a global (simulated annealing) or local (Powell) minimization applicable to all model parameters. RESULTS: PKQuest was applied to measurements of human propranolol pharmacokinetics and intestinal absorption. A meal has two effects: 1) increases portal blood flow by 50%; and 2) decreases liver metabolism by 20%. There is a significant delay in the oval propranolol absorption in fasting subjects that is absent in fed subjects. The oral absorption of the long acting form of propranolol continues for a period of more than 24 hours. CONCLUSIONS: PKQuest provides a new general purpose, easy to use, freely distributed and physiologically rigorous PBPK software routine. BioMed Central 2002-08-15 /pmc/articles/PMC126244/ /pubmed/12182760 http://dx.doi.org/10.1186/1472-6904-2-5 Text en Copyright © 2002 Levitt; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Research Article
Levitt, David G
PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol
title PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol
title_full PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol
title_fullStr PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol
title_full_unstemmed PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol
title_short PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol
title_sort pkquest: a general physiologically based pharmacokinetic model. introduction and application to propranolol
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC126244/
https://www.ncbi.nlm.nih.gov/pubmed/12182760
http://dx.doi.org/10.1186/1472-6904-2-5
work_keys_str_mv AT levittdavidg pkquestageneralphysiologicallybasedpharmacokineticmodelintroductionandapplicationtopropranolol